Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide Plus Radiation Therapy in Unfavorable Intermediate Risk Prostate Cancer
NCT05346848Phase 2Recruiting
- Sponsor
- Institut Bergonié
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Institut Bergonié. Started Feb 2023; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05346848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346848.